Evidence-Based Treatment of a Patient with Follicular Lymphoma by Rituximab_Chinese Journal of Evidence-Based Medicine

Authors：

 YANG Yingfang ¹ , LIU Bin ²

1. The Fourth People’s Hospital of Honghe State, Kaiyuan, Yunnan, 661600, China2. Department of Oncology, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

YANG Yingfang, Email: yangyingfang54@126.com

Keywords：

Foll icular lymphoma; Rituximab; Evidence-based treatment

DOI：

10.7507/1672-2531.20080029

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To formulate an evidence-based treatment for a patient newly diagnosed with follicular lymphoma.
Methods 　Based on the clinical questions we raised, evidence including systematic reviews and randomized controlled trials was collected from ACP Journal Club (1991 to November 2007), The Cochrane Library (Issue 4, 2007) and PubMed. The retrieved studies were further critically appraised.
Results 　The addition of rituximab to chemotherapy (R-chemo) was superior to chemotherapy alone in patients with follicular lymphoma. The regimen of CVP chemotherapy plus rituximab (R-CVP) was administered to the patient. After 4 courses of R-CVP, the patient had a complete response (CR).
Conclusion　 In newly diagnosed patients with follicular lymphoma, R-chemo is an effective treatment regimen.

Citation： YANG Yingfang,LIU Bin. Evidence-Based Treatment of a Patient with Follicular Lymphoma by Rituximab. Chinese Journal of Evidence-Based Medicine, 2008, 08(2): 134-136. doi: 10.7507/1672-2531.20080029 Copy

1.	Jaffe ES, Harris NL, Stein H,et al. World Health Organization classification of tumors pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer. 2001.
2.	Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin‘s lymphoma and chronic lymphocytic leukaemia. Drugs, 2003; 63(8): 803-843.
3.	Guyatt GH, Rennie D, Editors, The Evidence-Based Medicine Working Group. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago: AMA Press. 2002.
4.	Schulz H, Bohl ius JF, Trelle S,et al.Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst, 2007, 99(9): 706-714.
5.	Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 2005; 105(4): 1417-1423.
6.	Hiddemann W, Kneba M, Dreyling M,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin,vincristine,and prednisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 2005, 106(12): 3725-3732.
7.	Ogura M, Morishima Y, Kagami Y, et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci, 2006, 97(4): 305-312.
8.	Forstpointner R, Dreyl ing M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 2004, 104(10): 3064-3071.
9.	Herold M, Haas A, Srock S,et al. Rituximab added to first-line mitoxantrone,chlorambucil,and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.J Clin Oncol,2007,25(15):1986-1992.

1. Jaffe ES, Harris NL, Stein H,et al. World Health Organization classification of tumors pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer. 2001.
2. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin‘s lymphoma and chronic lymphocytic leukaemia. Drugs, 2003; 63(8): 803-843.
3. Guyatt GH, Rennie D, Editors, The Evidence-Based Medicine Working Group. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago: AMA Press. 2002.
4. Schulz H, Bohl ius JF, Trelle S,et al.Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst, 2007, 99(9): 706-714.
5. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 2005; 105(4): 1417-1423.
6. Hiddemann W, Kneba M, Dreyling M,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin,vincristine,and prednisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 2005, 106(12): 3725-3732.
7. Ogura M, Morishima Y, Kagami Y, et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci, 2006, 97(4): 305-312.
8. Forstpointner R, Dreyl ing M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 2004, 104(10): 3064-3071.
9. Herold M, Haas A, Srock S,et al. Rituximab added to first-line mitoxantrone,chlorambucil,and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.J Clin Oncol,2007,25(15):1986-1992.

Chinese Journal of Evidence-Based Medicine

Evidence-Based Treatment of a Patient with Follicular Lymphoma by Rituximab

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content